Biotechnology
Biopharmaceutical
Pharmaceutical

Fate Therapeutics

$18.57
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.98 (5.57%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell FATE and other stocks, options, ETFs, and crypto commission-free!

About FATE

Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Read More Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Employees
104
Headquarters
San Diego, California
Founded
2007
Market Cap
1.21B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
774.48K
High Today
$18.77
Low Today
$17.78
Open Price
$17.80
Volume
562.05K
52 Week High
$22.82
52 Week Low
$10.78

Collections

Biotechnology
Biopharmaceutical
Pharmaceutical
Health
Cancer Prevention
Therapy
Technology
2013 IPO

FATE News

ReutersAug 9

Edited Transcript of FATE earnings conference call or presentation 6-Aug-19 9:00pm GMT

24

FATE Earnings

-$0.37
-$0.32
-$0.27
-$0.22
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.33 per share
Actual
-$0.36 per share

More FATE News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.